Vitiligo is caused by the destruction of melanocytes, the cells that produce pigment in your skin. The primary driver is an autoimmune process where your own immune cells attack and kill melanocytes, but the reason this process starts in the first place involves a combination of genetic susceptibility, environmental exposures, oxidative stress, and physical triggers. About half of all cases develop before age 20, and the condition can appear suddenly or progress gradually over years.
The Autoimmune Attack on Pigment Cells
At the core of vitiligo is an immune system malfunction. Specific immune cells called CD8+ T cells, which normally fight infections, mistakenly identify melanocytes as threats and destroy them. The process begins when skin cells release chemical signals (CXCL9 and CXCL10) that act like a homing beacon, drawing these immune cells into the skin and directing them toward the exact layer where melanocytes live.
Once these T cells arrive and start destroying melanocytes, they release a signaling molecule called interferon-gamma, which recruits even more immune cells to the area. This creates a self-reinforcing cycle: the more melanocytes are destroyed, the stronger the immune signal becomes, pulling in more attackers. What makes vitiligo especially persistent is that some of these immune cells become “memory” cells that stay in the skin permanently. When new melanocytes try to migrate in from hair follicles to replenish pigment, these resident memory cells detect them and restart the attack. This is a key reason why vitiligo patches tend to recur in the same locations after treatment.
Genetics Set the Stage
You don’t inherit vitiligo directly, but you can inherit a genetic predisposition that makes your immune system more likely to target melanocytes. Researchers have identified dozens of genes linked to vitiligo risk, most of which are involved in immune regulation.
One of the strongest genetic associations is with a gene called HLA-A2, which roughly doubles the odds of developing vitiligo (an odds ratio of 2.07). HLA genes help your immune system distinguish your own cells from foreign invaders, so variations in these genes can make the immune system more prone to misidentifying melanocytes. Another gene, PTPN22, codes for a protein that acts as a brake on immune activation. Variants of this gene are also linked to several other autoimmune diseases, including type 1 diabetes and rheumatoid arthritis.
A third key gene, NLRP1, controls part of the body’s inflammatory response. Certain variants cause this gene to become overactive, leading to chronic low-level inflammation that can prime the immune system to attack melanocytes. Because vitiligo shares so many genetic risk factors with other autoimmune conditions, it frequently runs in families alongside those diseases.
Oxidative Stress and Cell Damage
Before the immune system even gets involved, oxidative stress may be the initial spark. Melanocytes are inherently vulnerable to damage from reactive oxygen species, including hydrogen peroxide, which accumulates naturally during the pigment-making process. In people with vitiligo, this buildup appears to be more severe, overwhelming the cell’s ability to neutralize it.
When oxidative stress damages melanocytes, it can expose internal proteins that the immune system doesn’t normally see. These exposed proteins may then be misrecognized as foreign, triggering the autoimmune cascade. The damage also disrupts the energy-producing structures inside melanocytes (mitochondria), further weakening the cells. This is why oxidative stress is considered critical for both the initiation and progression of vitiligo: it creates the conditions that allow the immune attack to begin.
Chemical Exposures That Trigger Depigmentation
Certain industrial and consumer chemicals can directly trigger vitiligo, particularly in people who are already genetically susceptible. The common thread among these chemicals is their molecular structure: they contain a phenol group that closely mimics tyrosine, an amino acid melanocytes use to build pigment. When melanocytes absorb these chemical imposters, the resulting disruption can damage or kill the cells and set off an immune response.
The list of known offenders is surprisingly long. Factory workers in leather manufacturing developed patchy depigmentation on their hands and arms from exposure to monobenzyl ether of hydroquinone, an antioxidant used in the process. Workers handling lubricating oils containing 4-tert-butylcatechol developed depigmentation on their extremities. Hospital workers exposed to certain disinfectants containing 4-tert-butylphenol or 4-tert-amylphenol lost pigment as well. Hair dyes containing para-phenylenediamine (PPD) have also been implicated.
Consumer products aren’t immune to this problem. A skin-lightening cream sold in Japan containing an ingredient called rhododendrol caused depigmentation in users, and while most people only lost pigment where the cream was applied, about 5% developed patches at sites they had never treated. This detail is important because it shows how a localized chemical exposure can sometimes ignite a bodywide autoimmune process. Traditional cosmetic dyes used in South Asia, called alta, have been reported to cause vitiligo at application sites as well.
Physical Trauma and the Koebner Phenomenon
Vitiligo can develop at sites of physical skin injury, a pattern known as the Koebner phenomenon. Cuts, burns, sunburns, friction from tight clothing, and even surgical scars can all become sites of new depigmentation. This occurs in most patients with vitiligo at some point during their disease course.
The mechanism likely ties back to the autoimmune process. Skin trauma causes local inflammation and cell damage, which can expose melanocyte proteins to the immune system and attract those melanocyte-targeting T cells to the injured area. If you already have vitiligo, the Koebner phenomenon is associated with more active disease overall and can signal that your condition is in a progressive phase.
Stress and the Nervous System Connection
Emotional and physical stress is one of the most commonly reported triggers before a vitiligo flare. The biological link involves your sympathetic nervous system, the “fight or flight” system. Stress triggers the release of catecholamines (stress hormones like noradrenaline), which cause blood vessels in the skin to constrict. This reduces oxygen supply and generates reactive oxygen species that can damage melanocytes directly.
Stress also increases production of neuropeptide Y (NPY), a signaling molecule found at elevated levels in the margins of vitiligo patches. NPY appears to exert a local effect on the skin’s autonomic nervous system that contributes to pigment loss. This neural component is especially relevant in segmental vitiligo, a form where depigmentation follows the path of a single nerve distribution on one side of the body, suggesting that nerve signaling plays a direct role in at least some forms of the disease.
Nutritional Factors
Low levels of certain nutrients appear in vitiligo patients more often than expected, though the evidence that deficiencies directly cause vitiligo remains limited. Vitamin D is the most studied: because it plays a role in immune regulation, low levels could theoretically make autoimmune misfires more likely. However, there isn’t yet strong enough evidence to conclude that low vitamin D causes vitiligo rather than simply coexisting with it.
Vitamin B12 and folic acid (B9) have shown more promising connections. In one study at the University of Alabama’s Birmingham Medical Center, 15 vitiligo patients were found to have low B12 and B9 levels, and after three years of supplementation, eight of them showed repigmentation. Phenylalanine, an amino acid involved in pigment production, has also shown benefit when combined with UV light therapy. In one clinical trial, 94.7% of patients experienced some repigmentation when oral phenylalanine was paired with UV-A exposure, compared to no improvement from either treatment alone.
Linked Autoimmune Conditions
Vitiligo rarely exists in isolation. About 14.3% of people with vitiligo also have autoimmune thyroid disease, and roughly 20.8% test positive for thyroid-specific antibodies even without a thyroid diagnosis yet. The relationship goes both ways: 2.7 to 7% of people with autoimmune thyroid disease also develop vitiligo.
Other conditions that cluster with vitiligo include type 1 diabetes, pernicious anemia (a B12 absorption disorder), rheumatoid arthritis, inflammatory bowel disease, psoriasis, and lupus. These associations reinforce that vitiligo is fundamentally a disease of immune dysregulation, and they share overlapping genetic risk factors. If you’ve been diagnosed with vitiligo, your doctor will often screen for thyroid problems in particular, given how frequently the two conditions overlap.